Royalty Pharma plans largest IPO of the year so far

Royalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. 

BMS launches COVID-19 delayed MS drug Zeposia in US

Bristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA

FDA extends review of Novartis' MS drug ofatumumab

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. 

Novartis builds case for MS drug ofatumumab as FDA decision ...

Novartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease activity for up to two years, as it waits for an FDA decisi

BMS gets FDA nod for ozanimod, but launch will be delayed

Macrophage Pharma goes for gold with new funding round

Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases.